GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (OTCPK:INCPF) » Definitions » Days Sales Outstanding

InnoCare Pharma (InnoCare Pharma) Days Sales Outstanding : 102.16 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is InnoCare Pharma Days Sales Outstanding?

InnoCare Pharma's average Accounts Receivable for the three months ended in Dec. 2023 was $31.54 Mil. InnoCare Pharma's Revenue for the three months ended in Dec. 2023 was $28.18 Mil. Hence, InnoCare Pharma's Days Sales Outstanding for the three months ended in Dec. 2023 was 102.16.

The historical rank and industry rank for InnoCare Pharma's Days Sales Outstanding or its related term are showing as below:

INCPF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 7.95   Med: 18.46   Max: 198.08
Current: 198.08

During the past 7 years, InnoCare Pharma's highest Days Sales Outstanding was 198.08. The lowest was 7.95. And the median was 18.46.

INCPF's Days Sales Outstanding is ranked worse than
82.51% of 892 companies
in the Biotechnology industry
Industry Median: 72.245 vs INCPF: 198.08

InnoCare Pharma's Days Sales Outstanding increased from Sep. 2022 (35.26) to Dec. 2023 (102.16).

InnoCare Pharma Days Sales Outstanding Historical Data

The historical data trend for InnoCare Pharma's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma Days Sales Outstanding Chart

InnoCare Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Sales Outstanding
Get a 7-Day Free Trial 11.28 24.45 7.95 51.80 100.78

InnoCare Pharma Quarterly Data
Dec17 Sep18 Dec18 Jun19 Sep19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.26 63.53 - 107.54 102.16

Competitive Comparison of InnoCare Pharma's Days Sales Outstanding

For the Biotechnology subindustry, InnoCare Pharma's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InnoCare Pharma's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InnoCare Pharma's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where InnoCare Pharma's Days Sales Outstanding falls into.


InnoCare Pharma Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

InnoCare Pharma's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

Days Sales Outstanding (A: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2022 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (18.354 + 38.763) / 2 ) / 103.434*365
=28.5585 / 103.434*365
=100.78

InnoCare Pharma's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding (Q: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Sep. 2023 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (24.324 + 38.763) / 2 ) / 28.175*365 / 4
=31.5435 / 28.175*365 / 4
=102.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InnoCare Pharma  (OTCPK:INCPF) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

InnoCare Pharma Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

InnoCare Pharma (InnoCare Pharma) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (OTCPK:INCPF) » Definitions » Days Sales Outstanding
Comparable Companies
HKSE:01541 HKSE:09966 HKSE:06660 HKSE:01952 HKSE:02162 HKSE:06826 HKSE:02315 HKSE:01530 HKSE:06955 HKSE:02105 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
09969:Hong Kong 33C:Germany 688428:China
Address
No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206
Website
https://www.innocarepharma.com
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.